• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, Oct. 23

Suven Life Sciences Ltd has secured three Indian product patents for its New Chemical Entities (NCEs) for the treatment of disorders associated with neuro degenerative diseases. According to a release, the patents (208688, 208714 and 209540) would be valid till 2022. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven. They are being developed as therapeutic agents and are useful in the treatment of cognitive impairment assoc iated with neuro-degenerative disorders like Alzheimer’s, attention deficient hyperactivity, Huntington’s, Parkinson’s and Schizophrenia.

— Our Bureau

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Accutest Labs expands clinical research

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line